Company profile RAIN
After 39 days of this quarter the interest is at 89.0. Based on that we can calculate that during remaining 52 days it will total up to 208.0. Rain Oncology expected interest is significantly higher compared to previous quarter (+163.3%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 12 | 51 325.0% QoQ | 45 -11.8% QoQ | 40 -11.1% QoQ |
| 2020 | 52 333.3% YoY 30.0% QoQ | 18 -64.7% YoY -65.4% QoQ | 37 -17.8% YoY 105.6% QoQ | 71 77.5% YoY 91.9% QoQ |
| 2021 | 86 65.4% YoY 21.1% QoQ | 45 150.0% YoY -47.7% QoQ | 72 94.6% YoY 60.0% QoQ | 33 -53.5% YoY -54.2% QoQ |
| 2022 | 75 -12.8% YoY 127.3% QoQ | 44 -2.2% YoY -41.3% QoQ | 49 -31.9% YoY 11.4% QoQ | 76 130.3% YoY 55.1% QoQ |
| 2023 | 185 146.7% YoY 143.4% QoQ | 287 552.3% YoY 55.1% QoQ | 95 93.9% YoY -66.9% QoQ | 79 3.9% YoY -16.8% QoQ |
| 2024 | 89 -51.9% YoY 12.7% QoQ | - | - | - |
The average 5 years interest of Rain Oncology was 5.9 per week. The last year interest of Rain Oncology compared to the last 5 years has changed by 113.9%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 273.37%.
There is not enough data for Rain Oncology Milademetan to provide analysis
There is not enough data for Rain Oncology Milademetan to provide correlation calculation
There is not enough data for Rain Oncology Milademetan to provide analysis
There is not enough data for MDM2-p53 inhibitor to provide analysis
There is not enough data for MDM2-p53 inhibitor to provide correlation calculation
There is not enough data for MDM2-p53 inhibitor to provide analysis
There is not enough data for precision oncology company to provide analysis
There is not enough data for precision oncology company to provide correlation calculation
There is not enough data for precision oncology company to provide analysis
There is not enough data for late-stage precision oncology to provide analysis
There is not enough data for late-stage precision oncology to provide correlation calculation
There is not enough data for late-stage precision oncology to provide analysis
There is not enough data for genetically select patients to provide analysis
There is not enough data for genetically select patients to provide correlation calculation
There is not enough data for genetically select patients to provide analysis
There is not enough data for oncogenic drivers to provide analysis
There is not enough data for oncogenic drivers to provide correlation calculation
There is not enough data for oncogenic drivers to provide analysis
After 39 days of this quarter the interest is at 331.0. Based on that we can calculate that during remaining 52 days it will total up to 772.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 345 | 488 41.4% QoQ | 490 0.4% QoQ | 500 2.0% QoQ |
| 2020 | 528 53.0% YoY 5.6% QoQ | 489 0.2% YoY -7.4% QoQ | 555 13.3% YoY 13.5% QoQ | 516 3.2% YoY -7.0% QoQ |
| 2021 | 478 -9.5% YoY -7.4% QoQ | 468 -4.3% YoY -2.1% QoQ | 441 -20.5% YoY -5.8% QoQ | 400 -22.5% YoY -9.3% QoQ |
| 2022 | 680 42.3% YoY 70.0% QoQ | 514 9.8% YoY -24.4% QoQ | 581 31.7% YoY 13.0% QoQ | 503 25.8% YoY -13.4% QoQ |
| 2023 | 723 6.3% YoY 43.7% QoQ | 597 16.1% YoY -17.4% QoQ | 603 3.8% YoY 1.0% QoQ | 665 32.2% YoY 10.3% QoQ |
| 2024 | 331 -54.2% YoY -50.2% QoQ | - | - | - |
The average 5 years interest of cancer therapies was 41.74 per week. The last year interest of cancer therapies compared to the last 5 years has changed by 21.59%. The interest for cancer therapies is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 32.4%.
After 34 days of this quarter the interest is at 422.0. Based on that we can calculate that during remaining 58 days it will total up to 1142.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 544 |
| 2019 | 956 75.7% QoQ | 951 -0.5% QoQ | 914 -3.9% QoQ | 975 79.2% YoY 6.7% QoQ |
| 2020 | 990 3.6% YoY 1.5% QoQ | 814 -14.4% YoY -17.8% QoQ | 936 2.4% YoY 15.0% QoQ | 929 -4.7% YoY -0.7% QoQ |
| 2021 | 869 -12.2% YoY -6.5% QoQ | 915 12.4% YoY 5.3% QoQ | 951 1.6% YoY 3.9% QoQ | 917 -1.3% YoY -3.6% QoQ |
| 2022 | 886 2.0% YoY -3.4% QoQ | 897 -2.0% YoY 1.2% QoQ | 859 -9.7% YoY -4.2% QoQ | 860 -6.2% YoY 0.1% QoQ |
| 2023 | 947 6.9% YoY 10.1% QoQ | 946 5.5% YoY -0.1% QoQ | 900 4.8% YoY -4.9% QoQ | 422 -50.9% YoY -53.1% QoQ |
The average 5 years interest of cancer treatment was 70.41 per week. The last year interest of cancer treatment compared to the last 5 years has changed by 0.24%. The interest for cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -1.58%.